Browse > Article
http://dx.doi.org/10.5483/BMBRep.2018.51.11.123

3-(Naphthalen-2-yl(propoxy)methyl)azetidine hydrochloride attenuates MPP+-induced cytotoxicity by regulating oxidative stress and mitochondrial dysfunction in SH-SY5Y cells  

Yang, Seung-Ju (Department of Biomedical Laboratory Science, Konyang University)
Yang, Ji Woong (Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine)
Na, Jung-Min (Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine)
Ha, Ji Sun (Department of Biomedical Laboratory Science, Konyang University)
Choi, Soo Young (Department of Biomedical Science and Research Institute for Bioscience and Biotechnology, Hallym University)
Cho, Sung-Woo (Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine)
Publication Information
BMB Reports / v.51, no.11, 2018 , pp. 590-595 More about this Journal
Abstract
Parkinson's disease (PD) is a common chronic neurodegenerative disease mainly caused by the death of dopaminergic neurons. However, no complete pharmacotherapeutic approaches are currently available for PD therapies. 1-methyl-4-phenylpyridinium $(MPP^+)$-induced SH-SY5Y neurotoxicity has been broadly utilized to create cellular models and study the mechanisms and critical aspects of PD. In the present study, we examined the role of a novel azetidine derivative, 3-(naphthalen-2-yl(propoxy)methyl)azetidine hydrochloride (KHG26792), against $MPP^+$-induced neurotoxicity in SH-SY5Y cells. Treatment of KHG26792 significantly attenuated $MPP^+$-induced changes in the protein levels of Bcl-2 and Bax together with efficient suppression of $MPP^+$-induced activation of caspase-3 activity. KHG26792 also attenuated mitochondrial potential and levels of ROS, $Ca^{2+}$, and ATP in $MPP^+$-treated SH-SY5Y cells. Additionally, KHG26792 inhibited the induced production of nitric oxide and malondialdehyde. Moreover, the protective effect of KHG26792 is mediated through regulation of glutathione peroxidase and GDNF levels. Our results suggest a possibility that KHG26792 treatment significantly protects against $MPP^+$-induced neurotoxicity in SH-SY5Y cells and KHG26792 may be a valuable therapeutic agent for the treatment of PD induced by an environmental toxin.
Keywords
Azetidine derivative; Mitochondrial dysfunctions; $MPP^+$; Oxidative stress;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chung HK, Kim OY, Lee H et al (2011) Relationship between dietary folate intake and plasma monocyte chemoattractant protein-1 and interleukin-8 in heart failure patients. J Clin Biochem Nutr 49, 62-66   DOI
2 Ho PW, Chu AC, Kwok KH et al (2006) Knockdown of uncoupling protein-5 in neuronal SHSY5Y cells: effects on $MPP^{+}$-induced mitochondrial membrane depolarization, ATP deficiency, and oxidative cytotoxicity. J Neurosci Res 84, 1358-1366   DOI
3 Liu B, Gao HM, Wang JY et al (2002) Role of nitric oxide in inflammation-mediated neurodegeneration. Ann NY Acad Sci 962, 318-331   DOI
4 Obata T (2006) Nitric oxide and $MPP^{+}$-induced hydroxyl radical generation. J Neural Transm 113, 1131-1144   DOI
5 Yurekli VA, Gurler S, Naziroglu M et al (2013) Zonisamide attenuates $MPP^{+}$-induced oxidative toxicity through modulation of $Ca^{2+}$ signaling and caspase-3 activity in neuronal PC12 cells. Cell Mol Neurobiol 33, 205-212   DOI
6 Lin LF, Doherty DH, Lile JD et al (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130-1132   DOI
7 d'Anglemont de Tassigny X, Pascual A and Lopez-Barneo J (2015) GDNF based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease. Front Neuroanat 9, 10
8 Lindholm D, Makela J, Di Liberto V et al (2016) Current disease modifying approaches to treat Parkinson's disease. Cell Mol Life Sci 73, 1365-1379   DOI
9 Cheng YF, Zhu G, Wu QW et al (2017) GPR30 activation contributes to the puerarin-mediated neuroprotection in $MPP^{+}$-induced SH-SY5Y cell death. J Mol Neurosci 61, 227-234   DOI
10 Gazewood JD, Richards DR and Clebak K (2013) Parkinson disease: an update. Am Fam Physician 87, 267-273
11 Smeyne M and Smeyne RJ (2013) Glutathione metabolism and Parkinson's disease. Free Radic Biol Med 62, 13-25   DOI
12 Malkus KA, Tsika E and Ischiropoulos H (2009) Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener 4, 24   DOI
13 Han Y, Han M, Shin D et al (2012) Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors. J Med Chem 55, 8188-8192   DOI
14 Bloem BR, Irwin I, Buruma OJ et al (1990) The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J Neurol Sci 97, 273-293   DOI
15 Cleeter MW, Cooper JM and Schapira AH (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 58, 786-789   DOI
16 Yi F, He X and Wang D (2013) Lycopene protects against $MPP^{+}$-induced cytotoxicity by maintaining mitochondrial function in SH-SY5Y cells, Neurochem Res 38, 1747-1757   DOI
17 Ojha S, Javed H, Azimullah S et al (2016) Betacaryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease. Mol Cell Biochem 418, 59-70   DOI
18 Lowe JT, Lee MD, Akella LB et al (2012) Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries. J Org Chem 77, 7187-7211   DOI
19 Dalla Y, Singh N, Jaggi AS et al (2009) Potential of ezetimibe in memory deficits associated with dementia of Alzheimer's type in mice. Indian J Pharmacol 41, 262-267   DOI
20 Kim J, Kim SM, Na JM et al (2016) Protective effect of 3-(naphthalen-2-yl(propoxy)methyl)azetidine hydrochloride on hypoxia-induced toxicity by suppressing microglial activation in BV2 cells. BMB Rep 49, 687-692   DOI
21 Kim EA, Na JM, Kim J et al (2017) Neuroprotective effect of 3-(naphthalen-2-yl(propoxy)methyl) azetidine hydrochloride on brain ischaemia/reperfusion injury. J Neuroimmune Pharmacol 12, 447-461   DOI
22 Borner C (2003) The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 39, 615-647   DOI
23 Kim EA, Choi J, Han AR et al (2013) Anti-oxidative and anti-inflammatory effects of 2-cyclopropylimino-3-methyl-1,3-thiazoline hydrochloride on glutamate-induced neurotoxicity in rat brain. Neurotoxicol 38, 106-114   DOI
24 Cho CH, Kim J, Ahn JY et al (2015) N-adamantyl-4-methylthiazol-2-amine suppresses lipopolysaccharideinduced brain inflammation by regulating $NF-{\kappa}B$ signaling in mice. J Neuroimmunol 289, 98-104   DOI
25 Rosa AI, Fonseca I, Nunes MJ et al (2017) Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson's disease. Biochim Biophys Acta-Mol Basis Dis 1863, 2171-2181   DOI
26 Hu XL, Song Q, Li X et al (2017) Neuroprotective effects of Kukoamine A on neurotoxin-induced Parkinson's model through apoptosis inhibition and autophagy enhancement. Neuropharmacology 117, 352e363   DOI
27 Choi WS, Yoon SY, Chang II et al (2000) Correlation between structure of Bcl-2 and its inhibitory function of JNK and caspase activity in dopaminergic neuronal apoptosis. J Neurochem 74, 1621-1626
28 Ghosh A, Chandran K, Kalivendi SV et al (2010) Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic Biol Med 49, 1674-1684   DOI
29 Ramalingam M and Kim SJ (2014) The role of insulin against hydrogen peroxide-induced oxidative damages in differentiated SH-SY5Y cells. J Recept Signal Transduct 34, 212-220   DOI
30 Song JX, Shaw PC, Wong NS et al (2012) Chrysotoxine, a novel bibenzyl compound selectively antagonizes $MPP^{+}$, but not rotenone, neurotoxicity in dopaminergic SH-SY5Y cells. Neurosci Lett 521, 76-81   DOI